L. Michael Glodé, MD, FACP

L. Michael Glodé, MD, FACP

[types usermeta='affiliation' user_is_author='true'][/types]

[types usermeta='location' user_is_author='true'][/types]

Dr. Glodé was the first board-certified Medical Oncologist at the University of Colorado, joining the faculty after training at Dana-Farber Cancer Institute. Dr. Glodé's research has been clinically focused on prostate cancer for many years. He headed the initial research on leuprolide, leading to it’s approval and subsequently developed a “single shot” castration agent that is in animal trials. He has also led efforts to evaluate a natural product, silibinin as a preventive or therapeutic agent and has been an investigator on more than 30 clinical trials, including the PI position for the largest adjuvant trial in prostate cancer, SWOG 9921. He has received numerous teaching awards and founded the AACR course “Molecular Biology for Clinical Oncologists” as well as serving as Founding Editor of the ASCO website, www.asco.org.

Articles by L. Michael Glodé, MD, FACP

TMPRSS2, ACE 2, and the Potential Role of 5ARIs and GNRH Analogues in Inhibiting COVID-19 Infection

L. Michael Glodé, MD, FACP, Professor Emeritus at the University of Colorado Cancer Center and a medical oncologist at the Shaw Regional Cancer Center in Edwards, Colorado, discusses the mechanism of action of the TMPRSS2 and ACE2 pathways, and their relationship to the host-cell entry of COVID-19. He goes on to discuss a clinical trial using the serine protease inhibitor Camostat, noting how 5ARIs and GNRH analogues could act as a target for prevention and possible treatment of COVID-19. He also discusses the results of an Italian observational study which demonstrated how prostate cancer patients receiving ADT appear to be partially protected from COVID-19 infection.

Read More

Join the GRU Community

- Why Join? -